Immunomodulator AS101 restores colistin susceptibility of clinical colistin-resistant Escherichia coli and Klebsiella pneumoniae in vitro and in vivo

IF 4.9 2区 医学 Q1 INFECTIOUS DISEASES International Journal of Antimicrobial Agents Pub Date : 2024-08-06 DOI:10.1016/j.ijantimicag.2024.107285
{"title":"Immunomodulator AS101 restores colistin susceptibility of clinical colistin-resistant Escherichia coli and Klebsiella pneumoniae in vitro and in vivo","authors":"","doi":"10.1016/j.ijantimicag.2024.107285","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>Colistin (COL) was once considered to be the last line of defence against multidrug-resistant bacteria belonging to the family <em>Enterobacteriaceae</em>. Due to the misuse of COL, COL-resistant (COL-R) <em>Enterobacteriaceae</em> have emerged. To address this clinical issue and combat COL resistance, novel approaches are urgently needed.</p></div><div><h3>Methods</h3><p>In this study, the in vitro and in vivo antimicrobial and antibiofilm effects of the immunomodulator AS101 were investigated in combination with COL against COL-R <em>Escherichia coli</em> (<em>E. coli</em>) and <em>Klebsiella pneumoniae</em> (<em>K. pneumoniae</em>).</p></div><div><h3>Results</h3><p>Checkerboard assay, time-kill assay, and scanning electron microscopy confirmed the in vitro antimicrobial phenotype, whereas, crystal violet staining and multidimensional confocal laser scanning microscopy with live/dead staining confirmed the antibiofilm capability of the combination therapy. Moreover, the <em>Galleria mellonella</em> infection model and the mouse infection model indicated the high in vivo efficacy of the combination therapy. Additionally, cytotoxicity experiments performed using human kidney-derived HK-2 cells and haemolysis assays performed using human erythrocytes collectively demonstrated safety at effective combination concentrations. Furthermore, quantification of the expression of inflammatory cytokines via enzyme-linked immunosorbent assay confirmed the anti-inflammatory advantage of combination therapy. At the mechanistic level, changes in outer and inner membrane permeability and accumulation of ROS levels, which might be potential mechanisms for synergistic antimicrobial effects.</p></div><div><h3>Conclusions</h3><p>This study found that AS101 can restore COL susceptibility in clinical COL-R <em>E. coli</em> and <em>K. pneumoniae</em> and also has synergistic antibiofilm and anti-inflammatory capabilities. This study provided a novel strategy to combat clinical infections caused by COL-R <em>E. coli</em> and <em>K. pneumoniae</em>.</p></div>","PeriodicalId":13818,"journal":{"name":"International Journal of Antimicrobial Agents","volume":null,"pages":null},"PeriodicalIF":4.9000,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Antimicrobial Agents","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0924857924002036","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives

Colistin (COL) was once considered to be the last line of defence against multidrug-resistant bacteria belonging to the family Enterobacteriaceae. Due to the misuse of COL, COL-resistant (COL-R) Enterobacteriaceae have emerged. To address this clinical issue and combat COL resistance, novel approaches are urgently needed.

Methods

In this study, the in vitro and in vivo antimicrobial and antibiofilm effects of the immunomodulator AS101 were investigated in combination with COL against COL-R Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae).

Results

Checkerboard assay, time-kill assay, and scanning electron microscopy confirmed the in vitro antimicrobial phenotype, whereas, crystal violet staining and multidimensional confocal laser scanning microscopy with live/dead staining confirmed the antibiofilm capability of the combination therapy. Moreover, the Galleria mellonella infection model and the mouse infection model indicated the high in vivo efficacy of the combination therapy. Additionally, cytotoxicity experiments performed using human kidney-derived HK-2 cells and haemolysis assays performed using human erythrocytes collectively demonstrated safety at effective combination concentrations. Furthermore, quantification of the expression of inflammatory cytokines via enzyme-linked immunosorbent assay confirmed the anti-inflammatory advantage of combination therapy. At the mechanistic level, changes in outer and inner membrane permeability and accumulation of ROS levels, which might be potential mechanisms for synergistic antimicrobial effects.

Conclusions

This study found that AS101 can restore COL susceptibility in clinical COL-R E. coli and K. pneumoniae and also has synergistic antibiofilm and anti-inflammatory capabilities. This study provided a novel strategy to combat clinical infections caused by COL-R E. coli and K. pneumoniae.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
免疫调节剂 AS101 可在体外和体内恢复临床耐大肠杆菌和肺炎克雷伯菌对大肠菌素的敏感性。
可乐定(COL)曾一度被认为是抵抗肠杆菌科多重耐药细菌的最后一道防线。由于滥用 COL,出现了对 COL 耐药(COL-R)的肠杆菌科细菌。为解决这一临床问题并对抗 COL 耐药性,迫切需要新的方法。本研究研究了免疫调节剂 AS101 与 COL 联用对 COL-R 大肠埃希菌(大肠杆菌)和肺炎克雷伯菌(肺炎克雷伯菌)的体外和体内抗菌和抗生物膜作用。棋盘试验、时间杀伤试验和扫描电子显微镜证实了体外抗菌表型,而水晶紫染色和多维共焦激光扫描显微镜活/死染色证实了联合疗法的抗生物膜能力。此外,黑线梭菌感染模型和小鼠感染模型也表明,该组合疗法在体内具有很高的疗效。此外,利用人体肾脏衍生的 HK-2 细胞进行的细胞毒性实验和利用人体红细胞进行的溶血实验共同证明了有效组合浓度下的安全性。此外,通过酶联免疫吸附试验(ELISA)对炎症细胞因子的表达进行量化,证实了联合疗法的抗炎优势。在机理层面,外膜和内膜通透性的变化以及 ROS 水平的积累,可能是协同抗菌作用的潜在机制。总之,本研究发现 AS101 可恢复临床 COL-R 大肠杆菌和肺炎双球菌对 COL 的敏感性,同时还具有协同抗生物膜和抗炎能力。这项研究为抗击由 COL-R 大肠杆菌和肺炎双球菌引起的临床感染提供了一种新策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
21.60
自引率
0.90%
发文量
176
审稿时长
36 days
期刊介绍: The International Journal of Antimicrobial Agents is a peer-reviewed publication offering comprehensive and current reference information on the physical, pharmacological, in vitro, and clinical properties of individual antimicrobial agents, covering antiviral, antiparasitic, antibacterial, and antifungal agents. The journal not only communicates new trends and developments through authoritative review articles but also addresses the critical issue of antimicrobial resistance, both in hospital and community settings. Published content includes solicited reviews by leading experts and high-quality original research papers in the specified fields.
期刊最新文献
International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page Advances in Virus-Specific T Cell Therapy for Polyomavirus Infections: A Comprehensive Review. Antibiotic Resistance of Helicobacter pylori in Mainland China: A Focus on Geographic Differences through Systematic Review and Meta-analysis. Epidemiology of subsequent Carbapenem-Resistant Enterobacterales (CRE) infection among rectal carriers: a meta-analysis of incidence, risk factors and their association with geographic region and age. In-host intra- and inter-species transfer of blaKPC-2 and blaNDM-1 in Serratia marcescens and its local and global epidemiology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1